Analysts Offer Insights on Healthcare Companies: Zogenix (NASDAQ: ZGNX) and Aslan Pharmaceuticals (NASDAQ: ASLN)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNXResearch Report) and Aslan Pharmaceuticals (ASLNResearch Report) with bullish sentiments.

Zogenix (ZGNX)

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Zogenix, with a price target of $60.00. The company’s shares closed last Monday at $46.99.

According to TipRanks.com, Byrnes has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 34.4% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Opiant Pharmaceuticals, and Aridis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $63.71 average price target, which is a 37.8% upside from current levels. In a report issued on November 18, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $60.00 price target.

See today’s analyst top recommended stocks >>

Aslan Pharmaceuticals (ASLN)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals, with a price target of $2.00. The company’s shares closed last Monday at $1.73.

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -21.5% and a 23.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals with a $1.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.